# Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Study · id `cardio:ct-nct02334254` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02334254](<https://clinicaltrials.gov/study/NCT02334254>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02334254

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.

## Technical summary

Registry record NCT02334254. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 420 participants (planned count; ClinicalTrials.gov record NCT02334254, source copy `cardio:ctgov-nct02334254-2015-01-08`, retrieved 2026-10-26)
- Start date: 2013-08 (registry gives no type) (ClinicalTrials.gov record NCT02334254, source copy `cardio:ctgov-nct02334254-2015-01-08`, retrieved 2026-10-26)
- Primary completion: 2016-01 (anticipated) (ClinicalTrials.gov record NCT02334254, source copy `cardio:ctgov-nct02334254-2015-01-08`, retrieved 2026-10-26)
- Completion: 2016-01 (anticipated) (ClinicalTrials.gov record NCT02334254, source copy `cardio:ctgov-nct02334254-2015-01-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02334254, source copy `cardio:ctgov-nct02334254-2015-01-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02334254-2015-01-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
- Condition: Atrial Fibrillation
- Intervention (Drug): rivaroxaban and ticagrel therapy
- Intervention (Drug): triple antithrombotic regimen with warfarin, asipirin and clopidogrel
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 5949e2b0ea6f2a4b67c4deee6934fce0cbc4c6c3a2c95df8e8f3d093dc399ffd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
